Logo image
Back
Placeholder TextIntraarticular steroids as DMARD-sparing agents for juvenile idiopathic arthritis flares: Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry
Journal article   Open access   Peer reviewed

Placeholder TextIntraarticular steroids as DMARD-sparing agents for juvenile idiopathic arthritis flares: Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry

Timothy Hahn, Carrie Daymont, Timothy Beukelman, Brandt Groh, Kimberly Hays, Catherine April Bingham, Lisabeth Scalzi and CARRA Registry investigators
Pediatric rheumatology online journal, Vol.20(1), pp.107-107
11/25/2022
DOI: 10.1186/s12969-022-00770-y
PMCID: PMC9701017
PMID: 36434731
url
https://doi.org/10.1186/s12969-022-00770-yView
Published (Version of record) Open Access

Abstract

Children with juvenile idiopathic arthritis (JIA) who achieve a drug free remission often experience a flare of their disease requiring either intraarticular steroids (IAS) or systemic treatment with disease modifying anti-rheumatic drugs (DMARDs). IAS offer an opportunity to recapture disease control and avoid exposure to side effects from systemic immunosuppression. We examined a cohort of patients treated with IAS after drug free remission and report the probability of restarting systemic treatment within 12 months. We analyzed a cohort of patients from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry who received IAS for a flare after a period of drug free remission. Historical factors and clinical characteristics and of the patients including data obtained at the time of treatment were analyzed. We identified 46 patients who met the inclusion criteria. Of those with follow up data available 49% had restarted systemic treatment 6 months after IAS injection and 70% had restarted systemic treatment at 12 months. The proportion of patients with prior use of a biologic DMARD was the only factor that differed between patients who restarted systemic treatment those who did not, both at 6 months (79% vs 35%, p < 0.01) and 12 months (81% vs 33%, p < 0.05). While IAS are an option for all patients who flare after drug free remission, it may not prevent the need to restart systemic treatment. Prior use of a biologic DMARD may predict lack of success for IAS. Those who previously received methotrexate only, on the other hand, are excellent candidates for IAS.
 Registries Rheumatology Antirheumatic Agents - therapeutic use Arthritis, Juvenile - drug therapy Biological Products - therapeutic use Child Humans Steroids - therapeutic use

Details

Metrics

3 Record Views
8 Times Cited - Web of Science
Logo image